Geode Capital Management
MIRM icon

Geode Capital Management’s Mirum Pharmaceuticals MIRM Stock Holding History

Geode Capital Management’s Portfolio MIRM Stock Details MIRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$116M Buy
1,260,003
+197,077
+19% +$18.5M 0.01% 989
2025
Q4 		$84M Buy
1,062,926
+52,904
+5% +$3.8M 0.01% 1197
2025
Q3 		$74.1M Sell
1,010,022
-19,594
-2% -$1.25M ﹤0.01% 1242
2025
Q2 		$52.4M Buy
1,029,616
+65,951
+7% +$2.94M ﹤0.01% 1394
2025
Q1 		$43.4M Buy
963,665
+20,321
+2% +$958K ﹤0.01% 1457
2024
Q4 		$39M Buy
943,344
+7,147
+0.8% +$298K ﹤0.01% 1591
2024
Q3 		$36.5M Buy
936,197
+29,017
+3% +$1.16M ﹤0.01% 1633
2024
Q2 		$31M Buy
907,180
+210,041
+30% +$5.51M ﹤0.01% 1681
2024
Q1 		$17.5M Buy
697,139
+15,959
+2% +$439K ﹤0.01% 2004
2023
Q4 		$20.1M Buy
681,180
+106,100
+18% +$3.21M ﹤0.01% 1922
2023
Q3 		$18.2M Buy
575,080
+49,518
+9% +$1.36M ﹤0.01% 1879
2023
Q2 		$13.6M Buy
525,562
+107,348
+26% +$2.85M ﹤0.01% 2103
2023
Q1 		$10M Buy
418,214
+18,532
+5% +$422K ﹤0.01% 2248
2022
Q4 		$7.79M Buy
399,682
+20,180
+5% +$399K ﹤0.01% 2422
2022
Q3 		$7.97M Buy
379,502
+98,642
+35% +$2.37M ﹤0.01% 2397
2022
Q2 		$5.46M Buy
280,860
+84,422
+43% +$1.99M ﹤0.01% 2656
2022
Q1 		$4.33M Buy
196,438
+23,545
+14% +$480K ﹤0.01% 2880
2021
Q4 		$2.76M Sell
172,893
-3,780
-2% -$58.8K ﹤0.01% 3211
2021
Q3 		$3.52M Buy
176,673
+2,402
+1% +$39.1K ﹤0.01% 3116
2021
Q2 		$3.01M Buy
174,271
+1,841
+1% +$33K ﹤0.01% 3142
2021
Q1 		$3.42M Buy
172,430
+60,218
+54% +$1.15M ﹤0.01% 2966
2020
Q4 		$1.96M Buy
112,212
+2,285
+2% +$44.9K ﹤0.01% 3100
2020
Q3 		$2.12M Buy
109,927
+5,387
+5% +$116K ﹤0.01% 2851
2020
Q2 		$2.03M Buy
104,540
+11,182
+12% +$187K ﹤0.01% 2826
2020
Q1 		$1.31M Buy
93,358
+34,790
+59% +$571K ﹤0.01% 2898
2019
Q4 		$1.44M Buy
58,568
+37,510
+178% +$400K ﹤0.01% 3142
2019
Q3 		$211K Buy
+21,058
New +$258K ﹤0.01% 3745

Other funds holding MIRM

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Geode Capital Management's MIRM Position: Q1 2026 in Review

Geode Capital Management increased its Mirum Pharmaceuticals (MIRM) stake by 19% in Q1 2026, buying an estimated $18.5M and bringing the position to 1,260,003 shares worth $116M. The position accounts for 0.01% of the portfolio, ranked #989.

Geode Capital Management first reported a position in MIRM in Q3 2019 and has held it in 27 quarters since. 311 funds tracked by Wall St. Rank hold MIRM as of Q1 2026.

  • Geode Capital Management held 1,260,003 shares of Mirum Pharmaceuticals worth $116M as of Q1 2026.
  • Geode Capital Management bought 197,077 Mirum Pharmaceuticals shares in Q1 2026, an estimated $18.5M.
  • Mirum Pharmaceuticals made up 0.01% of Geode Capital Management's portfolio in Q1 2026, its #989 holding.
  • Geode Capital Management first reported a position in Mirum Pharmaceuticals in Q3 2019 and has held it in 27 quarters since.
  • 311 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q1 2026.

Based on Geode Capital Management's 13F filing for Q1 2026, filed 15 May 2026.